Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €23.06 EUR
Change Today -0.57 / -2.40%
Volume 398.6K
QIA On Other Exchanges
Symbol
Exchange
Xetra
NASDAQ GS
As of 3:09 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Manfred E. Karobath M.D.

Vice-Chairman of the Supervisory Board, Chairman of Compensation Committee, Member of Science & Technology Committee and Member of Selection & Appointment (Nomination) Committee, Qiagen NV
AgeTotal Calculated CompensationThis person is connected to 20 board members in 3 different organizations across 3 different industries.

See Board Relationships
73$92,834

Background*

Dr. Manfred E. Karobath, M.D., served as the President of research and development and Executive Vice President of Rhne-Poulenc Rorer (now sanofi-aventis), a pharmaceutical company, from 1992 to 1999. In 1980, Dr. Karobath joined Sandoz Pharma in Basel, first, in drug discovery and served as Senior Vice President and Head of R&D, Switzerland. Dr. Karobath serves as the Chairman and Director of IDEA AG and Director of Cardion AG. Dr. Karobath serves as vice-chairman of ...

Read Full Background

Corporate Headquarters*

Spoorstraat 50
Venlo, Limburg 5911 KJ

Netherlands

Phone: 31 77 320 8400
Fax: 31 77 320 8409

Board Members Memberships*

Chairman of the Board and Member of Supervisory Board
1999-Present
Director and Member of Compensation Committee

Education*

Bachelor's Degree
Universitat Wien
MD
University of Vienna Medical School

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

Exercisable Options29,314
Unexercisable Options521
Total Number of Options29,835

Total Compensation*

Total Annual Cash Compensation$92,834
Total Calculated Compensation$92,834
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QIA:GR €23.06 EUR -0.57

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John L. Bishop Chairman, Chief Executive Officer and Member of Equity Incentive Committee
Cepheid
$664.9K
Peter D. Meldrum Ph.D.Chief Executive Officer, President and Director
Myriad Genetics Inc.
$997.0K
Stephen P. MacMillan Chief Executive Officer, President and Director
Hologic Inc.
$792.3K
Robert F. Friel Chairman, Chief Executive Officer, President and Member of Finance Committee
PerkinElmer Inc.
$1.0M
Alexandre Merieux Chief Executive Officer, Director and Member of Strategy Committee
bioMérieux SA
€544.9K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.